Covid-19 tracking
On April 6, Kaifa Pharmaceutical Co., Ltd. released the global multicenter phase III clinical key data results of prochloramide in the treatment of mild and moderate covid-19. Among the people taking prochloramide for more than one day, the hospitalization rate of prochloramide decreased by 50% (8 cases in the control group vs 4 cases in the treatment group, P value not published). Among the people taking prochloramide for more than seven days, the hospitalization rate of prochloramide decreased by 100% (6 cases in the control group vs 0 cases in the treatment group, P 0.02).
On April 5, the United States stopped using sotrovimab, the neutralizing antibody of GSK / vir. Based on the current data, FDA believes that sotrovimab is unlikely to treat omicronba 2 variant is effective, while ba 2 variant has become the mainstream strain at present.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) donated Lianhua Qingwen to Shanghai and Jilin to help prevent and control the epidemic.
\u3000\u3000OmicronBA. 2. Accounting for 59% in the world; The epidemic situation in Asian countries gradually eased, but the mortality rate in Hong Kong continued to rise to 1%; The number of new cases in Europe continued to peak and fall, and the number of hospitalizations and deaths showed lagging growth. The mortality rate of confirmed patients in the world is stable within 1%.
Zhou viewpoint update
A number of innovative drugs made progress this week: pemetinib, a biological FGFR inhibitor of Cinda, was approved for the treatment of cholangiocarcinoma. A number of innovative drugs and combination therapies have been incorporated into breakthrough therapies, including Zhengda Tianqing PD-L1 monoclonal antibody tqb2450 for endometrial cancer, Cinda bio’s ibi310 + cindilimab (PD1 + CTLA4) for advanced cervical cancer, and Chinese biopharmaceutical tqb3525 (PI3K) for recurrent / refractory follicular lymphoma. And platinum medicine cldn18 2 / CD3 double anti hbm7022’s global equity license is licensed to AstraZeneca, and platinum medicine will receive an advance payment of US $25 million and a milestone payment of up to US $325 million, as well as royalties based on future hbm7022 sales.
Continue to be optimistic about the annual report and quarterly report of CXO sector. The CXO sector will continue to receive the centralized disclosure of the annual report / first quarter report in April. The industry is in a high boom, and the sector performance and orders continue to improve. It is expected that the market sentiment will further pick up, and the valuation has room for further improvement and repair.
Continue to be optimistic about the upstream API sector of the industrial chain and the upstream pharmaceutical supply chain: ① the dual path growth of industrial upgrading (cdmo) + industrial extension of the API sector is expected to continue to improve the profitability of the API sector in 2022. ② We are optimistic about the investment opportunities in the supply chain during the 14th Five Year Plan period (industrial upgrading + domestic substitution), including equipment and equipment, scientific instruments, upstream reagent consumables for scientific research, upstream consumables for pharmaceutical industry and raw and auxiliary material packaging materials, especially the upstream supply chain for short-term epidemic prevention and control.
Investment suggestions:
It is suggested to focus on the two main lines of high performance growth and epidemic prevention and control. Epidemic prevention and control mainly includes detection and killing, vaccines and specific drugs and their R & D industrial chain, upstream supply chain, etc., with emphasis on vaccines, specific drugs (domestic and foreign) and their R & D industrial chain and the direction of traditional Chinese medicine anti epidemic.
It is suggested to pay attention to: Wuxi Apptec Co.Ltd(603259) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Hangzhou Tigermed Consulting Co.Ltd(300347) , Nanjing Vazyme Biotech Co.Ltd(688105) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , etc.
Risk tips
Covid-19 epidemic development and change risk, product R & D data and progress are less than expected risk, product capacity and sales are less than expected risk, government orders are less than expected risk, policy risk, etc.
